{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:11:06Z","timestamp":1790518266205,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Research Program of China","award":["81173120, 2012ZX09506001-004, 2013ZX09303005"],"award-info":[{"award-number":["81173120, 2012ZX09506001-004, 2013ZX09303005"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.ejpb.2014.06.012","type":"journal-article","created":{"date-parts":[[2014,6,26]],"date-time":"2014-06-26T16:16:42Z","timestamp":1403799402000},"page":"759-767","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Cyclosporin A affects the bioavailability of ginkgolic acids via inhibition of P-gp and BCRP"],"prefix":"10.1016","volume":"88","author":[{"given":"Li","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-qing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-yun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-hong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-ying","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-di","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-shan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2014.06.012_b0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00005082-200207000-00004","article-title":"Ginkgo biloba for the prevention and treatment of cardiovascular disease: a review of the literature","volume":"16","author":"Mahady","year":"2002","journal-title":"J. Cardiovasc. Nurs."},{"key":"10.1016\/j.ejpb.2014.06.012_b0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0300-483X(02)00189-0","article-title":"In vitro evaluation of the cytotoxic potential of alkylphenols from Ginkgo biloba L.","volume":"177","author":"Hecker","year":"2002","journal-title":"Toxicology"},{"key":"10.1016\/j.ejpb.2014.06.012_b0015","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1351\/pac199062071251","article-title":"Molecular recognition in allergic contact dermatitis to natural products","volume":"62","author":"Benezra","year":"1990","journal-title":"Pure Appl. Chem."},{"key":"10.1016\/j.ejpb.2014.06.012_b0020","article-title":"Studies on the reproductive, cytological and biochemical toxicity of Ginkgo biloba in Swiss albino mice","author":"Qureshi","year":"2006","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejpb.2014.06.012_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(01)01237-7","article-title":"Ginkgolic acids induce neuronal death and activate protein phosphatase type-2C","volume":"430","author":"Ahlemeyer","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejpb.2014.06.012_b0030","first-page":"735","article-title":"Chemistry and biology of alkylphenols from Ginkgo biloba L.","volume":"52","author":"Jaggy","year":"1997","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejpb.2014.06.012_b0035","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1159\/000317750","article-title":"Antitumor effects of ginkgolic acid in human cancer cell occur via cell cycle arrest and decrease the Bcl-2\/Bax ratio to induce apoptosis","volume":"56","author":"Zhou","year":"2010","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ejpb.2014.06.012_b0040","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1248\/cpb.37.1619","article-title":"A quantitative structure\u2013activity relationship for antitumor activity of long-chain phenols from Ginkgo biloba L.","volume":"37","author":"Itokawa","year":"1989","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejpb.2014.06.012_b0045","first-page":"651","article-title":"Study on the antibacterial activity of ginkgolic acids","volume":"25","author":"Yang","year":"2002","journal-title":"Zhong Yao Cai"},{"key":"10.1016\/j.ejpb.2014.06.012_b0050","doi-asserted-by":"crossref","first-page":"BR293","DOI":"10.12659\/MSM.883261","article-title":"Ginkgolic acid inhibits HIV protease activity and HIV infection in vitro","volume":"18","author":"L\u00fc","year":"2012","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.ejpb.2014.06.012_b0055","first-page":"555","article-title":"Determination of ginkgolic acids by high performance liquid chromatography","volume":"37","author":"Yang","year":"2002","journal-title":"Yao Xue Xue Bao"},{"key":"10.1016\/j.ejpb.2014.06.012_b0060","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrc2789","article-title":"ABC transporters in cancer: more than just drug efflux pumps","volume":"10","author":"Fletcher","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2014.06.012_b0065","series-title":"Handbook of Anticancer Pharmacokinetics and Pharmacodynamics","first-page":"373","article-title":"ABC transporters: involvement in multidrug resistance and drug disposition","author":"Massey","year":"2014"},{"key":"10.1016\/j.ejpb.2014.06.012_b0070","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1021\/jm3004398","article-title":"Chalcogenopyrylium compounds as modulators of the ATP-binding cassette transporters P-glycoprotein (P-gp\/ABCB1) and multidrug resistance protein 1 (MRP1\/ABCC1)","volume":"55","author":"Ebert","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2014.06.012_b0075","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejps.2003.07.003","article-title":"The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability","volume":"21","author":"Chan","year":"2004","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.06.012_b0080","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/jps.23069","article-title":"Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2","volume":"101","author":"Mease","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.06.012_b0085","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2013.11.013","article-title":"Evaluation of blood\u2013brain barrier and blood\u2013cerebrospinal fluid barrier permeability of 2-phenoxy-indan-1-one derivatives using in vitro cell models","volume":"460","author":"Hu","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.06.012_b0090","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1592\/phco.26.11.1601","article-title":"Role of P-glycoprotein in statin drug interactions","volume":"26","author":"Holtzman","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejpb.2014.06.012_b0095","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/jps.10408","article-title":"Biological, pharmaceutical, and analytical considerations with respect to the transport media used in the absorption screening system, Caco-2","volume":"92","author":"Ingels","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.06.012_b0100","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ijpharm.2013.05.053","article-title":"The interaction between human breast cancer resistance protein (BCRP) and five bisbenzylisoquinoline alkaloids","volume":"453","author":"Tian","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.06.012_b0105","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jep.2013.08.061","article-title":"In vitro characterization of ABC transporters involved in the absorption and distribution of liensinine and its analogs","volume":"150","author":"Yu","year":"2013","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejpb.2014.06.012_b0110","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1007\/s11095-009-9896-0","article-title":"Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs","volume":"26","author":"Matsson","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2014.06.012_b0115","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3109\/00498254.2012.702247","article-title":"The two enantiomers of tetrahydropalmatine are inhibitors of P-gp, but not inhibitors of MRP1 or BCRP","volume":"42","author":"Sun","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejpb.2014.06.012_b0120","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1021\/mp200487h","article-title":"Transfected MDCK cell line with enhanced expression of CYP3A4 and P-glycoprotein as a model to study their role in drug transport and metabolism","volume":"9","author":"Kwatra","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2014.06.012_b0125","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3748\/wjg.v10.i9.1365","article-title":"Establishment of a P-glycoprotein substrate screening model and its preliminary application","volume":"10","author":"Wang","year":"2004","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejpb.2014.06.012_b0130","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00280-007-0676-4","article-title":"Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals","volume":"62","author":"Nabekura","year":"2008","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.ejpb.2014.06.012_b0135","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.jchromb.2010.08.009","article-title":"Development of high performance liquid chromatography\/electrospray ionization mass spectrometry for assay of ginkgolic acid (15:1) in rat plasma and its application to pharmacokinetics study","volume":"878","author":"Xia","year":"2010","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejpb.2014.06.012_b0140","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0021-9673(01)01194-3","article-title":"Preparative isolation and dual column high-performance liquid chromatography of ginkgolic acids from Ginkgo biloba","volume":"930","author":"van Beek","year":"2001","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ejpb.2014.06.012_b0145","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.toxlet.2005.07.001","article-title":"In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride","volume":"160","author":"Fotakis","year":"2006","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.ejpb.2014.06.012_b0150","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1021\/mp900193e","article-title":"Effect of HEPES buffer on the uptake and transport of P-glycoprotein substrates and large neutral amino acids","volume":"7","author":"Luo","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2014.06.012_b0155","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/sj.bjp.0703150","article-title":"Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and Caco-2 cell monolayers","volume":"129","author":"Soldner","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejpb.2014.06.012_b0160","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1158\/1078-0432.CCR-04-1725","article-title":"Cyclosporin A is a broad-spectrum multidrug resistance modulator","volume":"11","author":"Qadir","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2014.06.012_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2009.05.022","article-title":"Permeation of astilbin and taxifolin in Caco-2 cell and their effects on the P-gp","volume":"378","author":"Wang","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.06.012_b0170","first-page":"278","article-title":"Pharmacokinetics, tissue distribution and excretion studies of ginkgolic acid (17:1) in rats","volume":"33","author":"Li","year":"2014","journal-title":"Lat. Am. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.06.012_b0175","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1023\/B:PHAM.0000016238.44452.f1","article-title":"Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors","volume":"21","author":"Yang","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2014.06.012_b0180","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.2002.12.116","article-title":"Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918","volume":"20","author":"Kruijtzer","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2014.06.012_b0185","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1054\/bjoc.2000.1543","article-title":"Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients","volume":"84","author":"Malingre","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejpb.2014.06.012_b0190","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.tips.2005.11.009","article-title":"Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs","volume":"27","author":"Breedveld","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejpb.2014.06.012_b0195","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.addr.2008.08.007","article-title":"Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice","volume":"61","author":"Vlaming","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2014.06.012_b0200","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-409X(98)00085-4","article-title":"P-glycoprotein, a gatekeeper in the blood\u2013brain barrier","volume":"36","author":"Schinkel","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2014.06.012_b0205","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1124\/dmd.112.049148","article-title":"Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood\u2013brain barrier: a small-animal positron emission tomography and in vitro study","volume":"41","author":"Bankstahl","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejpb.2014.06.012_b0210","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1021\/mp1003898","article-title":"Double-transduced MDCKII cells to study human p-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood\u2212brain barrier","volume":"8","author":"Poller","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2014.06.012_b0215","first-page":"3458","article-title":"P-glycoprotein (Mdr1a\/1b) and breast cancer resistance protein (Bcrp) decrease the uptake of hydrophobic alkyl triphenylphosphonium cations by the brain","volume":"2013","author":"Porteous","year":"1830","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejpb.2014.06.012_b0220","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/brain\/awr298","article-title":"Blood\u2013brain barrier P-glycoprotein function in Alzheimer\u2019s disease","volume":"135","author":"van Assema","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.ejpb.2014.06.012_b0225","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1517\/17425255.2012.668184","article-title":"Efflux transporters in the blood\u2013brain interfaces-in vitro and in vivo methods and correlations","volume":"8","author":"Krajcsi","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641114002045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641114002045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T23:27:39Z","timestamp":1565566059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641114002045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0939641114002045"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2014.06.012","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclosporin A affects the bioavailability of ginkgolic acids via inhibition of P-gp and BCRP","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2014.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}